A Phase 2 interventional study of Silver diamine fluoride gel and Silver diamine fluoride solution in Early Childhood Caries, sponsored by The University of Hong Kong. Active, not recruiting at 1 site in China. Open to participants aged 3 Years to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by The University of Hong Kong · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Heart Arrest with a site in China — 17 open to participants now, 22 under way, none of them phase 3. Heart Arrest · China.
Among the 37 studies in Heart Arrest with a site in China, this one is one of 4 that started in 2024, is the only one in phase 2, reaches primary completion later than 12 of the 21 other live ones, and was the 22nd registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →17 of the 37 studies in Heart Arrest with a site in China are open now. Recruiting first, the newest first:
Xiangya Hospital of Central South University · Sites in China
Ages 18–80
Central China Fuwai Hospital of Zhengzhou University · Sites in China
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–75
Tang Ziren · Sites in China
Ages 18+
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 3 Years to 5 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 630 is above the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 299 across the 9 interventional studies, 300 across the 28 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 37 have an industry lead sponsor. The 10 most frequent:
The University of Hong Kong is the lead sponsor of 1,295 studies on the registry; 351 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
The University of Hong Kong has 1 study filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
5 of the studies in Heart Arrest with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07113769Central China Fuwai Hospital of Zhengzhou UniversityPlasma Biomarkers and Platelet Morphology of Extracorporeal CardioPulmonary Resuscitation | 2026-12-30 |
| NCT06353334Tang ZirenButylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial) | 2026-12-31 |
| NCT06974682Capital Medical UniversityEffect of Target Temperature Management on Intestinal Flora and Its Metabolites in Patients With Cardiac Arrest | 2027-06-01 |
| NCT06992843Xiangya Hospital of Central South UniversityNeuroprotection Bundles For Comatose Survivors Following Cardiac Arrest | 2027-08 |
| NCT06241261The University of Hong KongArresting Early Childhood Caries With a Silver Diamine Fluoride Gel | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 37 studies in Heart Arrest with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective is to determine whether the efficacy of a 38% silver diamine fluoride (SDF) gel is non-inferior to a 38% SDF solution for arresting carious lesions in preschool children when applied at half-yearly intervals over a 30-month period.
Aim: Silver diamine fluoride (SDF) is typically available as a 38% aqueous solution, which is runny and difficult to apply. A 38% SDF gel has been introduced but it has not been tested clinically. The objective is to determine whether the efficacy of a 38% SDF gel is non-inferior to a 38% SDF solution for arresting carious lesions in preschool children.
Methods / Design: This non-inferiority randomised clinical trial will recruit 630 3- to 4-year-old children to receive either SDF gel or SDF solution on their carious lesions every 6 months. The primary outcome is the proportion of active carious tooth surfaces that arrest at the 30-month follow-up. The same examiner will conduct all examinations at the kindergartens over 30 months. The examiner, the children, and the children's parents will be blinded to treatments. The parents will be surveyed on their child's oral health-related behaviours and socioeconomic background to allow adjustment for effect modification.
Significance: If the result is as anticipated, SDF gel will prolong contact of SDF with the carious lesion to promote remineralisation. As SDF gel is cost-effective, simple, non-invasive, and non-aerosol-generating, it can be widely recommended for caries control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
38% silver diamine fluoride gel
Drug: Silver diamine fluoride gel
38% silver diamine fluoride solution
Drug: Silver diamine fluoride solution
Application of 38% SDF gel every 6 months
Also known as: SDF gel
Application of 38% SDF solution every 6 months
Also known as: SDF solution
The hardness of cavity on tooth by probing
The number of active carious tooth surfaces that become arrested per child
Time frame: The follow-up oral examinations will be conducted every 6 months for 30 months totally
Plan to share: No
Started Jan 2024 (actual). Primary completion is estimated for Aug 2027, 43 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Silver diamine fluoride